Compare · AIMT vs CHMA
AIMT vs CHMA
Side-by-side comparison of Aimmune Therapeutics, Inc. (AIMT) and Chiasma, Inc. (CHMA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIMT and CHMA operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- Company
- Aimmune Therapeutics, Inc.
- Chiasma, Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Chiasma, Inc.
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
Latest AIMT
- SEC Form SC 13G/A filed
- Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California
- Nestlé completes acquisition of Aimmune Therapeutics
- Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
- Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
- Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation
- ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm
- Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc., (NASDAQ:CGIX)
- Nestlé commences tender offer for Aimmune Therapeutics, Inc.
- Nestlé commences tender offer for Aimmune Therapeutics, Inc.
Latest CHMA
- Amryt Reports Q3 2022 Financial and Operational Results
- Amryt Reports Record Q2 2022 Results
- SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer
- Amryt Reports Record Q1 2022 Results
- Amryt Announces 22% growth in FY 2021 Revenues to $222.5M
- SEC Form EFFECT filed by Chiasma, Inc.
- SEC Form 15-12B filed by Chiasma, Inc.
- SEC Form 4: STONEPINE CAPITAL, L.P. returned 6,770,000 units of Common Stock to the company
- SEC Form SC 13G/A filed by Chiasma, Inc. (Amendment)
- SEC Form S-8 POS filed by Chiasma, Inc.